June 10, 2008 -- The race is on for successful commercialization of glucose monitors that don't require diabetics to sample their blood. Just this spring, one of those contestants -- GlucoLight, a development-stage company -- was awarded a US Patent (#7,356,365) for the non-invasive method and apparatus of measuring tissue oximetry.
Now, a new market research report by Greystone Associates, "Noninvasive Glucose Monitors: Technologies, Devices and Commercialization Potential," explains how advances in sensing electronics and signal processing are paving the way. Noninvasive monitors now progressing through the development and clinical trial process include novel optical, RF, and spectroscopy systems.
"But the challenge of consistently and reliably measuring glucose levels noninvasively is a daunting technical challenge that must take into account the physiological variations and user needs of patients across a broad genetic and socioeconomic spectrum," the report says. "These monitors must be extremely accurate and reliable, and usable by almost anyone."
The report includes an assessment of the various product candidates for noninvasive glucose monitoring, plus profiles of market participants, technology risk factors, and analysis of regulatory and market factors.
According to the report, companies active in this sector "are as varied as the technology and engineering approaches they pursue." And, those that will successfully commercialize their products will be able to attract and manage financial resources over a protracted product development cycle.